skip to main content


The discovery of repeated DNA sequences leads to answers about immune system cancer

Russell Ryan, M.D., an assistant professor in the Department of Pathology at the University of Michigan Medical School and a member of the University of Michigan Health Rogel Cancer Center, and his team used a method called ChIP-Seq to map the regulatory elements that control gene expression in B-cell lymphomas, a cancer of the immune system, in sample B-cell cancer cell lines.

Rebounding at 87 after CNS lymphoma

For William Moldwin, 87, getting back to the life he was living before being diagnosed with cancer meant publishing a book, collecting a lifetime impact award, receiving the Spirit of Detroit Award from Detroit’s City Council for his work securing health and mental health services for underserved Detroit communities, and planning his second book.

Zanubrutinib found to be effective against lymphoma in majority of patients

In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma. Cancers shrunk in 80% of the 20 patients on the clinical trial with marginal zone lymphoma, with a fifth experiencing complete remission.

Researchers Achieve Elimination of Leukemia and Lymphoma Tumors in Mouse Models

STAT3 has been a major therapeutic target in the treatment of cancer. But it's largely been considered “undruggable” due to the difficulty of developing compounds to effectively inhibit its activity. Researchers at the U-M Rogel Cancer Center have a new approach to targeting STAT3.